Evidence map›Paper›PMID 32860737›Full record

Trial reportClinical and translational science2021

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P

Pierre-Eric Juif, Jasper Dingemanse, Peter Winkle, Mike Ufer

Open access · goldAbstract readClinical Trial, Phase IComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Lack of Effect of Cenerimod, a Selective S1PInternational journal of molecular sciences · 2022
    Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Pierre-Eric JuifDepartment of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.ORCID 0000-0002-4899-8768
Jasper DingemanseDepartment of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Peter WinkleAnaheim Clinical Trials, LLC, Anaheim, California, USA.
Mike UferDepartment of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Idorsia (Switzerland) · CHAnaheim Clinical Trials · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cenerimod is a sphingosine-1-phosphate 1 receptor (S1P

Indexed as

Administration, OralAdolescentAdultAgedArea Under CurveAsianDose-Response Relationship, DrugDouble-Blind MethodHalf-LifeHealthy VolunteersHeart RateHumansLupus Erythematosus, SystemicLymphocyte CountMaleMiddle AgedcenerimodOxadiazolesPropylene GlycolsS1PR1 protein, humanSphingosine-1-Phosphate Receptors

Identifiers

PMID32860737
PMCPMC7877840
OpenAlexW3082504908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.